Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO James Edgemond - CFO and Treasurer Leigh Peterson - EVP, Product Development and Xenotransplantation Pat Poisson - EVP, Technical Operations Dewey Steadman - Head, IR Conference Call Participants Roger Song - Jefferies Jessica Fye - JPMorgan Ash Verma - UBS ...

United Therapeutics Corporation Fourth Quarter 2024 Corporate Update February 26, 2025 INTRODUCTION Safe Harbor Statement All statements in this presentation are made as of February 26, 2025. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise. Statements included in this presentation that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of ...

United Therapeutics’ (UTHR) fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales.See the Zacks Earnings Calendar to stay ahead of market-making news.United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high-risk neuroblastoma.Revenues came in at $735.9 million, beati ...

United Therapeutics (UTHR) came out with quarterly earnings of $6.19 per share, beating the Zacks Consensus Estimate of $6.10 per share. This compares to earnings of $4.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.48%. A quarter ago, it was expected that this drugmaker would post earnings of $6.18 per share when it actually produced earnings of $6.39, delivering a surprise of 3.40%.Over the last four quarters, the comp ...

Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., February 26, 2025: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.01 per share UTHR Nasdaq Global Select Market Securi ...

Group 1 - United Therapeutics (NASDAQ: UTHR) is highlighted as a balanced investment opportunity in the biotechnology sector, showcasing high growth rates [1] - The company is positioned favorably for investors looking to enter the biotechnology market [1] Group 2 - The article emphasizes the importance of thorough research and analysis in navigating complex global markets [1]

Analysts on Wall Street project that United Therapeutics (UTHR) will announce quarterly earnings of $6.10 per share in its forthcoming report, representing an increase of 39.9% year over year. Revenues are projected to reach $725.32 million, increasing 18% from the same quarter last year.The consensus EPS estimate for the quarter has been revised 0.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates dur ...

Company Performance - United Therapeutics (UTHR) has returned 3.9% year-to-date, outperforming the Medical sector average loss of 3.9% [4] - AnaptysBio, Inc. (ANAB) has returned 8.5% year-to-date, also outperforming the Medical sector [5] Earnings Estimates - The Zacks Consensus Estimate for UTHR's full-year earnings has increased by 4.6% over the past 90 days, indicating stronger analyst sentiment [4] - AnaptysBio, Inc.'s consensus EPS estimate for the current year has increased by 24% over the past three months [5] Industry Performance - United Therapeutics is part of the Medical - Drugs industry, which has lost 9.2% year-to-date, making UTHR's performance better than its industry average [6] - AnaptysBio, Inc. is part of the Medical - Biomedical and Genetics industry, which has moved -12.6% since the beginning of the year [7] Sector and Industry Rankings - The Medical sector is ranked 1 in the Zacks Sector Rank, which includes 16 different groups [2] - United Therapeutics is a member of the Medical - Drugs industry, ranked 63 in the Zacks Industry Rank [6] - AnaptysBio, Inc. falls under the Medical - Biomedical and Genetics industry, ranked 64 in the Zacks Industry Rank [7] Stock Ratings - United Therapeutics currently has a Zacks Rank of 2 (Buy) [3] - AnaptysBio, Inc. also has a Zacks Rank of 2 (Buy) [5]

Stock Comparison - United Therapeutics (UTHR) and Stevanato Group (STVN) are two stocks from the Medical - Drugs sector that are being compared for their attractiveness to value investors [1] Valuation Metrics - UTHR has a forward P/E ratio of 12.64, while STVN has a forward P/E of 41.14 [5] - UTHR has a PEG ratio of 0.93, compared to STVN's PEG ratio of 8.35 [5] - UTHR has a P/B ratio of 2.65, while STVN has a P/B ratio of 5.81 [6] Zacks Rank and Value Grade - UTHR has a Zacks Rank of 2 (Buy), indicating positive revisions to earnings estimates, while STVN has a Zacks Rank of 4 (Sell) [3] - UTHR earns a Value grade of A, while STVN has a Value grade of C [6] Conclusion - UTHR shows stronger estimate revision activity and more attractive valuation metrics compared to STVN, making it the superior option for value investors at this time [7]